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Abstract
AIM: To identify a cost-effective strategy of second 
primary colorectal cancer (CRC) screening for cancer 
survivors in Korea using a decision-analytic model.
METHODS: A Markov model estimated the clinical 
and economic consequences of a simulated 50-year-
old male cancer survivors’ cohort, and we compared 
the results of eight screening strategies: no screening, 
fecal occult blood test (FOBT) annually, FOBT every 
2 years, sigmoidoscopy every 5 years, double contrast 
barium enema every 5 years, and colonoscopy every 
10 years (COL10), every 5 years (COL5), and every 
3 years (COL3). We included only direct medical costs, 
and our main outcome measures were discounted 
lifetime costs, life expectancy, and incremental cost-
effectiveness ratio (ICER).
RESULTS: In the base-case analysis, the non-dominat-
ed strategies in cancer survivors were COL5, and COL3. 
The ICER for COL3 in cancer survivors was $5593/life-
year saved (LYS), and did not exceed $10 000/LYS in 
one-way sensitivity analyses. If the risk of CRC in can-
cer survivors is at least two times higher than that in 
the general population, COL5 had an ICER of less than 
$10 500/LYS among both good and poor prognosis of 
index cancer. If the age of cancer survivors starting 
CRC screening was decreased to 40 years, the ICER of 
COL5 was less than $7400/LYS regardless of screening 
compliance.
CONCLUSION: Our study suggests that more strict 
and frequent recommendations for colonoscopy such 
as COL5 and COL3 could be considered as economically 
reasonable second primary CRC screening strategies for 
Korean male cancer survivors.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
A recent improvement in cancer survival owing to early 
diagnosis and advances in treatment has raised the issue 
of  second primary cancers (SPCs) in cancer survivors 
after their primary treatment[1,2]. Due to carcinogenic 
effects of  cancer-related treatment, genetic susceptibil-
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ity or unhealthy behavior such as smoking, alcohol and 
obesity, cancer survivors are at increased risk for SPCs, 
not only at the original site but at other sites as well[3,4]. 
Recent studies have shown that the age-standardized 
incidence rate was 2.3 times higher for an SPC than for 
a first cancer in the Korean general male population[5]. 
Specifically, the age-standardized incidence rate was 
about four times higher for second than for first primary 
colorectal cancers (CRCs)[5]. It is well-known that screen-
ing for CRC reduces mortality through detection of  ma-
lignancy at an earlier, more treatable stage as well as by 
identification and removal of  the precursor lesion, the 
adenomatous polyp[6]. These findings suggest that more 
thorough surveillance and screening for second primary 
CRC is needed for the cancer survivors. 
Many previous studies have focused on the cost-
effectiveness (CE) of  CRC screening in the general 
population[6-9], and several panels have recommended 
CRC screening for the general population[10-12]. As the 
risk of  CRC and life expectancy are quite different 
between cancer survivors and the general population, 
screening guidelines for the general population could 
not be applied to the cancer survivors. However, until 
now, there have been few recommendations for CRC 
screening for cancer survivors. To suggest a feasible 
economic strategy of  second primary CRC screening for 
cancer survivors in Korea, we constructed a decision-
analytic model, and compared the CE results of  cancer 
screening in cancer survivors and in the average-risk 
general population. 
MATERIALS AND METHODS
The natural history of  a simulated male cancer survivors’ 
cohort was modeled with and without second primary 
CRC screening until age of  75 years (Figure 1). For 
simplicity and comparison with results from the general 
population, we assumed that all male cancer survivors 
enter at age 50 years, which most guidelines for the gen-
eral population recommended for starting CRC screen-
ing[10-12]. We developed a Markov model using TreeAge-
Pro 2007 software (TreeAge Software Inc., Williamstown, 
Massachusetts). The Markov model estimated the clinical 
and economic consequences of  eight different screen-
ing strategies as follows: (1) no screening, (2) fecal occult 
blood test (FOBT) annually (FOBT1), (3) FOBT every 
2 years (FOBT2), (4) sigmoidoscopy every 5 years (SIG5), 
(5) double contrast barium enema every 5 years (DCBE5), 
(6) colonoscopy every 10 years (COL10), (7) colonoscopy 
every 5 years (COL5), and (8) colonoscopy every 3 years 
(COL3).
Individuals were placed into health states defined by 
the presence or absence of  a colorectal polyp or second 
primary CRC (early or advanced) 1 year after the index 
cancer diagnosis. Cases of  positive screening test results 
were worked up with a colonoscopy, and individuals 
diagnosed with polyps underwent polypectomy. The 
probability of  perforation was assigned to colonoscopy, 
sigmoidoscopy, DCBE and polypectomy[8,13,14]. Mortality 
caused by the risk of  perforation was assumed to be 
0.02%[9,14]. Colonoscopy was repeated every 3 years for 
surveillance after polypectomy[15]. We assumed that 80% 
of  male cancer survivors underwent the initial screening 
test, independent of  whether they were compliant with 
past tests. The compliance of  follow-up or surveillance 
colonoscopy was assumed to be 100%. We also assumed 
that 90% of  CRCs develop from polyps[15,16], and the 
latent period between early stage and advanced stage 
was assumed to be 2 years[9]. The relative risk of  CRC in 
Korean male cancer survivors was assumed to be four 
times higher than that in the general population[5]. Age-
specific transition probabilities and prevalence were 
calculated between normal, polyp, and CRC to yield an 
incidence rate of  polyp and CRC derived from previous 
literature and the Korea Central Cancer Registry[7,17-19]. 
The stage-specific CRC mortality were applied uniformly 
to all malignancies regardless of  the means of  detection 
(by symptoms or screening) or the state of  detection 
(diagnosed vs undiagnosed cancer). Age-specific mortality 
from index cancer and other causes was estimated based 
on the above sources combined with statistics published 
by the National Center for Health Statistics[20] and Korea 
Central Cancer Registry[21]. As there have been few studies 
on mortality from second primary CRC, we calculated 
the additional yearly probability of  dying from a second 
primary CRC based on cancer stage from previous studies 
of  CRC as the first index cancer[21-23]. 
We obtained the data on the costs of  CRC treatment 
by stage and time period from the National Health 
Insurance Corporation (social insurer of  the national 
health insurance (NHI) with a universal coverage of  
population)[24]. Costs of  screening tests were obtained 
from the fee schedule of  the National Health Insurance 
Corporation (the NHI of  Korea has a fee schedule 
applied to all insured services)[25]. Costs were expressed in 
US dollars and the exchange rate was 955 Korean Won for 
one US dollar in 2006[26]. As the indirect costs of  cancer 
screening are not established in Korea, we included only 
direct medical costs. 
Our main outcome measures were discounted lifetime 
costs, life expectancy, incremental cost-effectiveness 
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Figure 1  Markov model of second colorectal cancer (CRC) screening in 
Korean male cancer survivors.
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ratio (ICER), which were compared for different CRC 
screening strategies. Because there are uncertainties with 
respect to quality of  life associated with CRC screening, 
colorectal polyp, and second CRC, we conducted the 
base case analysis using increase in life expectancy as the 
primary outcome. Incremental CE analysis was performed 
by ranking the 16 strategies in order of  increasing 
effectiveness. After eliminating strategies that were more 
or equally costly and less effective than a competing 
strategy [i.e. ruled out by simple dominance), we calculated 
the ICER for each strategy (additional cost divided by life-
year saved (LYS)] compared with the next least expensive 
strategy. Strategies exhibiting extended dominance were 
eliminated from the rank-ordered list, and ICERs of  the 
remaining strategies were recalculated[27]. Future costs and 
life-years were discounted at an annual rate of  3%. We 
compared the results from male cancer survivors with that 
from general male population. 
Sensitivity analyses were performed to assess the 
stability of  the results of  a plausible range of  several 
parameters, such as prevalence of  colorectal polyps at 
age 50 years, 5-year survival rates of  second primary 
CRC, complications of  screening test or polypectomy etc 
(Table 1). We performed detailed analyses by changing 
key variables of  the index cancer such as 5-year survival 
rate of  first cancer, relative risk of  CRC in cancer 
survivors compared with that in general population. In 
addition, we evaluated the effects of  changing age of  
subjects for starting second primary CRC screening and 
compliance rate on the CE of  our results. 
RESULTS
Base case
In the base-case analysis at 80% screening compliance, 
all screening strategies extended life expectancy both in 
male cancer survivors and the general population (Table 2). 
The strategies which were not ruled out by simple 
www.wjgnet.com
Table 1  Summary of assumptions
Parameter Base case value (range) Ref.
Sensitivity & specificity of 
colorectal screening tests
Sensitivity of FOBT for colorectal polyps/cancer 0.1/0.5 [27-30]
Sensitivity of colonoscopy for colorectal polyps/cancer   0.9/0.95 [6,31,32]
Sensitivity of double contrast barium enema for colorectal polyps/cancer 0.5/0.8 [6,33,34]
Sensitivity of sigmoidoscopy for colorectal polyps/cancer 0.46/0.52 [31,32,35]
Specificity of FOBT    0.9 [28-30]
Specificity of colonoscopy 1 [6,31,32]
Specificity of double contrast barium enema    0.9 [6,33,34]
Specificity of sigmoidoscopy      0.95 [6,31,32]
Natural history of 
colorectal polyp/cancer 
sequence
Prevalence of polyps at age 50 yr 0.20 (0.1-0.4) [14,35]
Annual polyp incidence rate in cancer survivors Age specific [14,35,36]2
Percent of cancers originating as polyps 90% [37,38]
Relative risk of colorectal cancer in cancer survivor compared with the 
general population
4 (1-5) [5]
Age specific incidence rate of colorectal cancer without polypoid precursors 
in cancer survivors
Age specific [5,39,40]2
Age specific incidence rate of colorectal cancer with polypoid precursors in 
cancer survivors
Age specific [5,39,40]2
Dwelling time of colorectal cancer in early stages 2 yr [29,41]
Percent of colorectal cancers detected in early stages with no screening     5% (2%-10%) [23]
Five-year all cause survival for early 2nd primary colorectal cancer     90% (80%-95%) [18,22,23]
Five-year all cause survival for advanced 2nd primary colorectal cancer     60% (40%-70%) [18,22,23]
Natural history of cancer 
survivors
Five-year survival for index cancer     40% (20%-80%) [18]
Age specific mortality except the index cancer Age specific [21]
Age of cancer survivors for starting colorectal cancer screening, year 50 (40-60) [10-12]
Compliance of 2nd colorectal cancer screening       80% (60%-100%)
Complications and 
unintended consequences
Rate of perforation of colon in colonoscopy    0.20% (0.1%-0.3%) [13,14,42]
Rate of perforation of colon in polypectomy    0.40% (0.2%-0.5%) [13,14,42]
Rate of perforation from sigmoidoscopy          0.01% (0.005%-0.05%) [13,14,42]
Rate of perforation from double contrast barium enema        0.005% (0.001%-0.01%) [42]
Death rate due to perforated colon   0.2% (0.1%-5%) [19,39,42]
Cost (dollar1) & discount 
rate
Sigmoidoscopy      31.3 [25]
Colonoscopy      61.7 [25]
Double contrast barium enema      68.5 [25]
FOBT        2.7 [25]
Polypectomy, biopsy and pathologic exam 189 [25]
Treatment of early cancer for first year      7330 (5860-8800) [7,25]
Treatment of advanced cancer for first year        14 660 (10 050-15 080) [7,25]
Treatment of cancer after first year      2094 (1670-2510) [7,25]
Cost to repair the endoscopic perforation      3141 (2510-3770) [7]
Discount rate                   0.03 (0-0.05)
1Exchange rate: 955 Korean Won for one US dollar in 2006; 2Estimated by calibration to national data on colorectal polyp and cancer incidence.
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dominance nor extended dominance (non-dominated 
strategies) in the general population were COL10, COL5, 
and COL3, while those in cancer survivors were COL5 
and COL3. The ICER for COL3 in cancer survivors 
was $5593 per LYS. In cancer survivors, the lifetime 
total cost per person associated with “FOBT annually” 
was larger than that associated with no screening, while 
COL5 and COL3 were less costly than no screening.
Sensitivity analyses 
Figure 2 shows the results of  one-way sensitivity analyses 
on CE from the perspective of  COL3 vs COL5 in male 
cancer survivors. In most cases, COL5 and COL3 were 
non-dominated strategies, and the ICER of  COL3 ranged 
between $1480 and $9192.
Table 3 shows the results of  two-way sensitivity 
analyses by changing risk of  second CRC and 5-year 
survival rate of  index cancer in Korean male cancer 
survivors. If  the risk of  CRC in cancer survivors was 
at least three times higher than that in the general 
population, screening with COL5 in cancer survivors 
had an ICER of  less than $4000 per LYS in the entire 
range of  5-year survival of  index cancer between 20% 
and 80%. If  the risk of  CRC in cancer survivors was 
two times higher than that in the general population, 
COL5 in cancer survivors had an ICER of  less than 
$10 500 per LYS in both types of  index cancer with 
poor and good prognosis. If  the risk of  CRC in cancer 
survivors was the same as that in the general population, 
non-dominated strategies were no screening, COL10, 
COL5, and COL3, and the ICER of  COL5 was more 
than $25 000 per LYS, while the ICER of  COL10 ranged 
between $2315 in index cancer with good prognosis and 
$19 650 in index cancer with poor prognosis. 
Table 4 shows the results of  sensitivity analysis by 
changing compliance of  CRC screening and age of  cancer 
www.wjgnet.com
Table 2  Cost-effectiveness of colorectal screening strategies among male cancer survivors and the general population in Korea (80% 
compliance)





















dollar1 per life-year 
gained
COL every 10 yr   437.3 17.260 … COL every 5 yr 463.5 7.572
No screening   448.0 17.243 … COL every 10 yr 480.1 7.568 …
COL every 5 yr   478.3 17.263 14 456.8 COL every 3 yr 480.2 7.575 5592.9
DCBE every 5 yr   542.3 17.256 … DCBE every 5 yr 563.4 7.562 …
SIG every 5 yr   542.4 17.255 … SIG every 5 yr 571.8 7.560 …
COL every 3 yr   554.4 17.265 38 876.8 No screening 632.2 7.544 …
FOBT every 2 yr   810.0 17.252 … FOBT every 2 yr 735.2 7.557 …
FOBT every 1 yr 1130.9 17.257 … FOBT every 1 yr 842.3 7.564 …
COL: Colonoscopy; SIG: Sigmoidoscopy; DCBE: Double contrast barium enema; FOBT: Fecal occult blood test. Ellipse indicates no data (incremental CR 
ratios not calculated for these strategies because they were dominated). 1Exchange rate, 955 Korean Won for one US dollar in 2006; 2Incremental CE ratio 
(dollar/year) = Incremental cost per person/incremental years of life gained.
Discount rate (0-0.05)
Prevalence of polyps at age 50 yr (0.01-0.04)
Percent of colorectal cancers detected in early stages with no screening (2%-10%)
5-yr all cause survival for early colorectal cancer (80%-95%)
5-yr all cause survival for advanced colorectal cancer (40%-70%)
Rate of perforation of colon in colonoscopy (0.1%-0.3%)
Rate of perforation of colon in polypectomy (0.2%-0.5%)
Death rate due to perforation (0.1%-0.5%)
Medical expenditure of early colorectal cancer in first year ($3670-$7330)
Medical expenditure of advanced colorectal cancer in first year ($7370-$17 590)
Medical expenditure of colorectal cancer after first year ($1050-$3140)
Medical expenditure to repair the endoscopic perforation ($1570-$4710)
 0   1000  2000 3000  4000 5000  6000 7000  8000  9000 10 000
     Incremental cost-effectiveness ratio ($/life-year gained)
Figure 2  Sensitivity analyses on cost-effectiveness from the perspective of colonoscopy every 3 years vs colonoscopy every 5 years in male cancer 
survivors.
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survivors for starting CRC screening. If  the age of  cancer 
survivors for starting CRC screening was 50 years or 
older, COL3 had an ICER of  less than $14 600 per LYS, 
regardless of  the screening compliance. If  age for starting 
CRC screening in cancer survivors was 40 years, the ICER 
of  COL5 was less than $7400 per LYS saved in all cases 
of  CRC screening compliance.
DISCUSSION
We constructed a computer simulation to suggest 
economic strategies of  second primary CRC screening 
for cancer survivors in Korea, and compared the CE 
results of  CRC cancer screening in cancer survivors 
and in the average-risk general population. As all non-
dominated strategy were those using colonoscopy in 
both cancer survivors and the general population, more 
strict and frequent recommendation of  colonoscopy 
such as COL5 and COL3 could be considered economic 
strategies for male cancer survivors.
Until now, there has been no explicit threshold of  
CE below which policy makers will consider accepting 
the strategy. In the US, a figure of  $50 000 per Quality 
Adjusted Life-Year (QALY) has frequently been quoted 
www.wjgnet.com
Table 3  Two-way sensitivity analysis by changing variables of index cancer such as 5-yr survival rate of first cancer and relative risk 
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5 COL5 329.0 4.512 COL5 532.5 7.567 COL5 957.9 13.829
COL3 339.2 4.514      4921.7 COL3 542.2 7.571   2634.4 COL3 962.6 13.836     658.2
4 COL5 306.7 4.516  COL5 463.5 7.572  COL10 826.0 13.837  
COL3 329.0 4.517   18 078.3 COL3 480.2 7.575   5592.9 COL5 831.1 13.843     835.2
   COL3 879.7 13.847 11 508.2
3 COL10 266.6 4.517  COL10 401.4 7.576  COL10 682.9 13.847  
COL5 270.3 4.518      2685.2 COL5 409.6 7.579   3365.6 COL5 701.9 13.851   4104.9
COL3 295.5 4.519 27 126 COL3 447.3 7.580 22 760.2 COL3 761.9 13.854 18 922.1
2 No screening 185.4 4.512  COL10 324.4 7.582  COL10 533.5 13.857  
COL10 224.5 4.52    4912 COL5 340.1 7.583   9506.4 COL5 566.7 13.860 10 725.2
COL5 232.3 4.521      8378.3 COL3 383.7 7.584 39 469.5 COL3 638.6 13.862 34 075.6
COL3 260.4 4.522   45 556.4     
1 No screening   96.1 4.519  No screening 175.9 7.580  No screening 342.6 13.853  
COL10 180.5 4.523   20 568.2 COL10 244.0 7.587   9196.3 COL10 377.2 13.867   2424.5
COL5 192.4 4.524   25 817.6 COL5 267.2 7.588 28 343.9 COL5 425.1 13.869 31 064.6
COL3 223.5 4.524 103 111.0 COL3 316.8 7.589 91 808.0 COL3 509.3 13.870 81 681.8
COL10: Colonoscopy every 10 years; COL5: Colonoscopy every 5 years; COL3: Colonoscopy every 3 years; Dominated strategy is a strategy that is more or 
equally costly and less effective than a competing strategy. 1Exchange rate, 955 Korean won for one US dollar in 2006; 2Incremental CE ratio (dollar/year) = 
Incremental cost per person/Incremental years of life gained.
Table 4  Two-way sensitivity analysis on cost-effectiveness of 2nd primary colorectal cancer screening by compliance of screening 
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40 COL5 370.0 8.633 COL10 341.0 8.326  COL10 352.2 8.328  
COL3 388.9 8.636 7584.1 COL5 343.7 8.329     872.5 COL5 369.2 8.330   7375.9
 COL3 383.7 8.330 26 483.2 COL3 424.1 8.331 50 842.3
50 COL3 479.2 7.665 COL5 463.5 7.572  COL10 475.0 7.571  
 COL3 480.2 7.575    5592.9 COL5 476.0 7.574     330.8
  COL3 508.1 7.577 14 571.1
60 COL3 528.3 7.668 COL3 522.1 6.057  COL5 519.5 6.057  
    COL3 529.5 6.059   4186.7
COL10: Colonoscopy every 10 years; COL5: Colonoscopy every 5 years; COL3: Colonoscopy every 3 years. Dominated strategy is a strategy that is more or 
equally costly and less effective than a competing strategy. 1Exchange rate: 955 Korean Won for one US dollar in 2006. 2Incremental CE ratio (dollar/year) = 
Incremental cost per person/Incremental years of life gained.
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for many years as being cost-effective[43]. The World 
Health Report 2002 suggested that interventions costing 
less than three times Gross Domestic Product (GDP) 
per capita for each Disability Adjusted Life-Year (DALY) 
averted represented good value for money[44], which is 
usually well in excess of  $50 000 per QALY in many high-
income countries[43]. In our study, the ICER for COL3 
was less than $6000 per LYS in a base line analysis, and 
did not exceed $10 000 per LYS in one-way sensitivity 
analyses. Our findings also suggest that if  the risk of  
CRC in cancer survivors is at least two times higher than 
that in the general population, COL5 could be a cost-
effective strategy for second primary CRC screening for 
cancer survivors of  both good and poor prognosis of  
index cancer, with an ICER of  less than $10 500 per LYS. 
As our primary outcomes are not QALY or DALY, direct 
comparisons might be difficult. The GDP per capita 
of  Korea was more than $20 000 in 2006. When we 
approximately applied these CE thresholds, in most cases, 
COL5 and COL3 could be considered a cost-effective 
method for second primary CRC screening for Korean 
male cancer survivors, regardless of  the index cancer. 
Even if  the index cancer were CRC, our finding could 
be applied and be consistent with the CRC surveillance 
guidelines of  the American Society of  Clinical Oncology 
(ASCO)[45]. In ASCO guidel ines, routine annual 
colonoscopies are not recommended for all CRC patients, 
and colonoscopy every 3-5 years could be sufficient to 
detect new CRCs and polyps[45]. 
It is also important to consider the changes in CE 
of  these strategies according to age of  starting second 
primary CRC screening in cancer survivors. Little is 
known about the CE if  cancer survivors start second 
primary CRC screening above or below age 50, at which 
most guidelines recommend starting CRC screening in 
the general population. Our findings suggest that for 
male cancer survivors in older age, COL3 had more 
favorable CE results, regardless of  screening compliance. 
For younger cancer survivors aged 40 years old, COL5 
could be considered a CE strategy with ICER of  less 
than $7600 per LYS. 
Interestingly, in our study of  Korea, COL10, COL5 
and COL3 had lower total medical costs than no 
screening of  male cancer survivors. In other countries, 
screening for CRC usually leads to more costs than no 
screening. Cost estimates for the medical care of  CRC 
treatment in the US range from $25 000 to $70 000 and 
the cost of  COL is about $1000[9,16]. However, in Korea, 
the cost estimate of  CRC treatment in the first year 
ranges from $7000 to $14 000 while the cost of  COL 
was about $60[24,25]. The ratio of  treatment cost to COL 
cost ranges from 25:1 to 70:1 in the US and 120:1 to 
230:1 in Korea. Due to the difference in cost structures, 
screening with colonoscopy might be more cost-effective 
in Korea than in other countries. However, CRC 
screenings are not covered by the Korean NHI scheme 
in either the general population or cancer survivors. 
Instead, the Korean government started the national 
cancer screening program (NCSP) in 1999, which was 
extended to include CRC screening in 2004[11]. The 
government covers 50% of  the screening cost for the 
insured and 100% for low-income people. However, the 
primary method for CRC screening in the Korean NCSP 
is FOBT annually. Our study shows that the strategy 
of  “FOBT annually” is always the dominant strategy in 
male cancer survivors, and costs more than the strategy 
of  no screening. 
The major barrier to promotion of  colonoscopy as 
a primary CRC screening tool is the lack of  manpower 
to deliver colonoscopy to the public in Korea. In 
these human-resource limited setting, it is important 
to identify the more vulnerable population who has a 
greater potential to receive benefits. Our study suggests 
that cancer survivors who are at increased risk of  second 
primary CRC have a favorable result of  CE of  CRC 
screening compared with the general population. Even 
in younger cancer survivors aged 40 years old, COL5 
might be economically feasible, while COL10 is usually 
recommended for the Korean general population aged 
50 years old. Therefore, at least for cancer survivors, 
CRC screening should be covered by the Korean NHI 
scheme and screening methods using colonoscopy are 
needed to be recommended as a primary screening 
strategy for CRC in this population. 
Limitations
Our analysis has several limitations. In the design of  the 
model, we tried to reduce the complex natural history of  
CRC to a few essential states and to avoid assumptions 
on treatments for which little or no published data 
existed. For instance, we assumed that 90% of  second 
primary CRC arose from polyps. We used several sets 
of  data from the general population, such as prevalence 
of  colorectal polyp by age, polyp recurrence rate, and 
treatment costs of  second primary CRC, if  there were 
no published data available in cancer survivors. There 
were possible differences between these two populations. 
However, when we performed sensitivity analyses, the 
CE results were usually insensitive to the plausible range 
of  these uncertain parameters. Second, we calculated 
only the direct costs and did not take into account the 
impact of  CRC and screening on indirect costs. Third, in 
our study, recently developed CRC screening strategies 
such as CT colonoscopy were not included. However, 
the cost of  CT colonoscopy is about four times higher 
than that of  colonoscopy in Korea, while the sensitivity 
and specificity of  CT colonoscopy is not superior to that 
of  colonoscopy[46], and this new method does not seem 
to be an economically-efficient strategy. 
In conclusion, with an increased population of  
long-term cancer survivors, effective systems for their 
health promotion are needed. Implementation of  the 
economic SPC screening program might be one of  the 
important interventions to improve their health. Our 
study showed that COL3 or COL5 might be suggested 
as a primary strategy for second primary CRC screening 
in cancer survivors who have a higher risk of  CRC than 
the general population. This study supports the evidence 
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and rationale for second primary CRC screening in male 
cancer survivors. 
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Recent improvement in cancer survival due to early diagnosis and advances 
in treatment has raised the issue of second primary cancers (SPCs) in cancer 
survivors after their primary treatment. The age-standardized incidence rate is 
about four times higher for second primary colorectal cancer (CRC) than for first 
primary CRC in Korea. However, until now, there have been few recommenda-
tions and economic evaluations of CRC screening for cancer survivors.
Research frontiers 
To suggest a feasible economic strategy of second CRC screening for cancer 
survivors in Korea, the authors constructed a decision-analytic model, and 
compared the cost-effectiveness results of cancer screening between in male 
cancer survivors.
Innovations and breakthroughs
Non-dominated strategies were those using colonoscopy in both cancer survi-
vors and the general population, and more strict and frequent recommendations 
for colonoscopy (COL) such as COL5 (screening every 5 years) and COL3 
(screening every 3 years) could be considered as economic strategies for male 
cancer survivors.
Applications
The major barrier to promoting colonoscopy as a primary CRC screening tool 
is the lack of manpower to deliver colonoscopy to the public in Korea. In these 
human-resource limited settings, it is important to identify the most vulner-
able population who has more potential to receive the benefits. In younger 
cancer survivors aged 40 years old, COL5 might be economically feasible, 
while COL10 is usually recommended for the Korean general population aged 
50 years old. Therefore, at least for cancer survivors, CRC screening should 
be covered by the Korean national health insurance scheme and screening 
methods using colonoscopy should be recommended as a primary screening 
strategy for CRC in this population. 
Terminology
SPC: A SPC is a new primary cancer developing in a person with a history of 
cancer.
Peer review
The authors investigated the cost-effective strategy of CRC screening for can-
cer survivors in Korea. The article is well written and the contents are reliable. 
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